



Piramal Pharma Solutions launches rapid integrated approach ADCelerate

13 October 2022 | News

ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission

Piramal Pharma Solutions, Mumbai-based Contract Development and Manufacturing Organization (CDMO), has announced the launch of *ADCelerate*, a new, branded solution for antibody-drug conjugate drug development that accelerates timelines for developing the initial clinical supply of both drug substance and drug product.

With *ADCelerate*, Piramal Pharma Solutions (PPS) delivers fully developed manufacturing processes for antibody-drug conjugate drug substance and lyophilized drug product, all within as few as twelve months. The programme includes qualified, Phase I appropriate analytical methods to support batch release and stability studies for both drug substance and drug product, as well as initial stability data on drug substance (six months) and drug product (one month).

Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions said, "As a CDMO serving the biopharma industry, we recognize that speed matters. Getting our clients into the clinic as quickly as possible without compromising quality supports our ethos of patient centricity. *ADCelerate* is a strong example of this principle brought to life. By leveraging our capabilities and expertise in ADCs and sterile fill/finish, we are able to shorten timelines while maintaining the highest standards of quality."